FDA Philippines reminded the public about the use of the UK’s new antiviral drug.
The Food and Drug Administration (FDA) Philippines recently reminded the public about the use of the UK’s new antiviral drug in the Philippines.
This, as FDA Philippines on Friday released FDA Advisory No. 2020-1131 reminding the public about the use of dexamethasone. The said advisory came after the Department of Health reminded the public about the said drug.
Other Stories
- DOH Reminds Public: UK’s New Antiviral Drug ‘Not A Cure For COVID-19’
- New Antiviral Drug Can Help Save Lives Of Patients With Coronavirus Disease
- WHO Hails New Antiviral Drug As ‘Lifesaving Scientific Breakthrough’
In its advisory, the Food and Drug Administration strongly reminded the public that UK’s new antiviral drug Dexamethasone was “a prescription drug” and should “strictly” be used under the supervision of a licensed physician, adding that there were dexamethasone products that were currently registered with the Food and Drug Administration.
Moreover, dexamethasone should be only “dispensed by licensed establishments” to patients with valid prescription and the sale of unregistered dexamethasone as well as the sale of dexamethasone without valid prescription or via online platforms was strictly prohibited.
Dexamethasone was “a steroid drug” and was prescribed by a licensed physician which was based on the patient’s medical condition. The Food and Drug Administration reminded that misuse or unsupervised chronic use of dexamethasone may lead to serious adverse reactions including obesity, poor wound healing, osteoporosis, muscle weakness, gastrointestinal bleeding and ulcers, electrolyte imbalance, suppression of growth among infants and children, and immunosuppression.
What can you say about this? Let us know!
For more news and updates, follow Philippine Newspaper on Facebook!
